SGLT2 inhibitors and new frontiers in heart failure treatment regardless of ejection fraction and setting
{{output}}
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to reduce cardiovascular (CV) mortality and heart failure (HF) hospitalizations, independently from left ventricular ejection fraction (EF). Their efficacy has been assessed both in patients wi... ...
